Continuous Glucose Monitoring to Aid Weight Loss in Prediabetes

Last updated: January 12, 2023
Sponsor: Stanford University
Overall Status: Terminated

Phase

N/A

Condition

Diabetes Prevention

Diabetes (Pediatric)

Weight Loss

Treatment

N/A

Clinical Study ID

NCT03844646
49402
P30DK116074
  • Ages 18-99
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The primary objective of this study is to determine whether intermittent use of continuous glucose monitor will facilitate weight loss in individuals who are overweight/obese with prediabetes.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Overweight/obese (BMI 25-40 kg/m2)
  • Prediabetes (fasting glucose 100-125 mg/dL and/or HbA1c 5.7-6.4%)

Exclusion

Exclusion Criteria:

  • On glucose-lowering medications (e.g., metformin)
  • On weight-loss medications

Study Design

Total Participants: 12
Study Start date:
August 01, 2019
Estimated Completion Date:
December 31, 2021

Study Description

Continuous glucose monitoring (CGM) has revolutionized the treatment of patients on intensive insulin therapy and its utility can also be harnessed to help individuals with prediabetes make healthful lifestyle changes. Successful weight loss requires adherence to lower calories, regular exercise, and self-monitoring. This proposal will test the hypothesis that intermittent CGM will facilitate all of these components for successful weight loss by functioning as a continuous self-monitor and guiding healthful food choices and physical activity.

Connect with a study center

  • Stanford

    Stanford, California 94305
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.